Evidence map›Paper›PMID 33899946›Full record

ArticleThe Laryngoscope2021

Treatment Modalities and Survival Outcomes for Sinonasal Diffuse Large B-Cell Lymphoma.

Brandon M Lehrich, Arash Abiri, Khodayar Goshtasbi, Jack Birkenbeuel, Tyler M Yasaka, Peter Papagiannopoulos, Bobby A Tajudeen, Elizabeth A Brem, Edward C Kuan

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Sinonasal lymphoma: A primer for otolaryngologists.Laryngoscope investigative otolaryngology · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Brandon M LehrichDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0003-1003-5605
Arash AbiriDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0003-2656-1060
Khodayar GoshtasbiDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0002-0045-2547
Jack BirkenbeuelDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0002-2133-7708
Tyler M YasakaDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.
Peter PapagiannopoulosDepartment of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A.
Bobby A TajudeenDepartment of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A.
Elizabeth A BremDepartment of Hematology and Oncology, University of California, Irvine, California, U.S.A.
Edward C KuanDepartment of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, U.S.A.ORCID 0000-0003-3475-0718
University of California, Irvine · USRush University Medical Center · US

Funding

TRAINING PROGRAM FOR MD/PHD STUDENTST32GM008208 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STEINMAN, RICHARD A · 1987 to 2021
$15.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008620 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI GOLDIN, ALAN L · 1999 to 2023
$8.1M
NIGMS NIH HHS T32 GM008208NIGMS NIH HHS T32 GM008620
6 · The paper itself

Abstract

objectives/hypothesisThis study utilizes a large population national database to comprehensively analyze prognosticators and overall survival (OS) outcomes of varying treatment modalities in a large cohort of sinonasal diffuse large B-cell lymphoma (SN-DLBCL) patients. STUDY

designRetrospective database study.

methodsThe National Cancer Database was queried for all SN-DLBCL cases diagnosed from 2004 to 2015. Kaplan-Meier log-rank test determined differences in OS based on clinical covariates. Cox proportional-hazards analysis was used to determine clinical and sociodemographic covariates predictive of mortality.

resultsA total of 2,073 SN-DLBCL patients were included, consisting of 48% female with a mean age of 66.0 ± 16.2 years. Overall, 82% of patients were Caucasian, 74% had early-stage disease, and 49% had primary tumors in the paranasal sinuses. Early-stage patients were more likely to receive multi-agent chemoradiotherapy compared to multi-agent chemotherapy alone (P < .001). Multivariable Cox proportional-hazards analysis revealed chemoradiotherapy to confer significantly greater OS improvements than chemotherapy alone (hazard ratio [HR]: 0.61; P < .001). However, subset analysis of late-stage patients demonstrated no significant differences in OS between these treatment modalities (P = .245). On multivariable analysis of chemotherapy patients treated post-2012, immunotherapy (HR = 0.51; P = .024) demonstrated significant OS benefits. However, subset analysis showed no significant advantage in OS with administering immunotherapy for late-stage patients (P = .326). Lastly, for all patients treated post-2012, those receiving immunotherapy had significantly improved OS compared to those not receiving immunotherapy (P < .001).

conclusionsTreatment protocol selection differs between early- and late-stage SN-DLBCL patients. Early-stage patients receiving chemotherapy may benefit from immunotherapy as part of their treatment paradigm. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E2727-E2735, 2021.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsChemoradiotherapyCombined Modality TherapyFemaleHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingParanasal Sinus NeoplasmsProgression-Free SurvivalRetrospective StudiesSeverity of Illness IndexAntineoplastic AgentsB-cell lymphomachemoradiotherapyimmunotherapyNational Cancer Data Baseoverall survivalSinonasaltreatment

Identifiers

PMID33899946
PMCPMC8502199
OpenAlexW3159151254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.